DB06130ExperimentalProtein Based Therapies
FAV-201 is a patient-specific immunotherapy for the treatment of T-cell lymphoma.
- Primary indication
- Investigated for use/treatment in lymphoma (non-hodgkin's).Curator reviewed
- Code names
- FAV-201
Which companies are running trials of FAV-201, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account